Altogen Labs CRO
|File:Altogen Labs CRO Logo, May 2018.png|
|Industry||Contract research organizations|
|Headquarters||Austin, Texas, United States|
|Products||Contract Research, Pharmacology Services, Bioremediation Treatments|
Altogen Labs CRO is a contract research organization (CRO) based in Austin, Texas that is involved in pharmacological discovery and drug development. The company maintains a GLP-compliant laboratory for conducting cancer research, toxicology assays, and in vivo experiments.
Altogen Labs began performing preclinical animal studies in 2009 after establishing an IACUC-regulated laboratory. In 2011, the company began providing pyrosequencing services to hospitals and laboratories, a technique used in diagnosis of genetic diseases, such as those caused by excessive DNA methylation. Altogen Labs became a part of the Texas Venture Labs (at The University of Texas at Austin) in 2013. In 2016, Altogen Chemicals, a subsidiary of Altogen Labs, began manufacturing hexachlorodisilane for semiconductor and electronic applications. Altogen Labs was named one of the key players in the bioremediation market in 2018 by Transparency Market Research.
Altogen Labs provides GLP-compliant pharmacology and biotechnology contract research services. The company's products are focused on preclinical research, with xenograft models and high-throughput screening tailored to individual research. As part of its contract research program, Altogen Labs develops investigational new drugs and runs cytotoxicity studies in preparation for clinical trials. The company's clientele consists of hospitals, private laboratories, and the pharmaceutical industry.
Pre-Clinical and Laboratory Services
Altogen Labs' custom research services span several areas, involving both in vitro and in vivo research. Although catering to pharmaceutical applications, Altogen Labs also runs commercial biodistribution studies and bioremediation contracts. The company's major products fall into several categories:
Altogen runs drug testing services aimed at discerning the cytotoxicity of experimental drugs. Such research is primarily based on testing new drugs for potential negative side effects, and understanding the mechanism of action of novel compounds. Toxicology testing occurs in two stages; in vitro testing on cultured cells, and later testing in live organisms.
Stable Cell Line Development
In context of protein production and cell research, Altogen produces cell lines that have been genetically modified. Stable cell lines contrast with transiently-transfected cell lines, which remain genetically modified for a short period of time and cannot reproduce while keeping desired genetic mutations. 
Altogen Labs produces and tests in vivo tumor xenografts for drug development studies involving cancer growth in mammals. SCID mice are primarily used as the tumor recipients in xenografts, and drugs are tested on the mice to determine efficiency and side effects. Currently the company has 89 xenografts derived from cancer cell lines and 29 patient derived xenografts, which are used to evaluate metastasis, resistance, and other aspects of cancerous tissue in drug studies.
The company has RNAi technology products, involving the delivery of short sequences of RNA into cells for the purposes of gene expression and regulation. Such research involves the creation of specific siRNA strands used for individual experiments.
Altogen purifies site-specific bacterial strains for bioremediation purposes. The company holds a patent for the methods for isolating and selecting appropriate bacteria for each remediation site. In addition to being used in oil spills, such bacteria may also be used to remediate sites contaminated with persistent organic chemical spills, pesticides, herbicides, and other industrial and chemical manufacturing wastes.
- "Altogen Labs". BioSupply.net. 2 June 2014.
- "Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics". WRCBtv. 21 May 2018. Retrieved 30 May 2018.
- "Altogen Labs introduces pyrosequencing services for hospitals, research institutions". News Medical Life Sciences. 20 July 2011. Retrieved 30 May 2018.
- Lorek, Laura (31 January 2013). "11 Startups Join Texas Venture Lab's Spring 2013 Accelerator". Silicon Hills News.
- Ranjan, Vishal (3 June 2016). "Altogen Chemicals Launches Ultra-pure Hexachlorodisilane". Researz. Retrieved 30 May 2018.
- Roul, Ari (8 May 2018). "Bioremediation Technologies and Services Market: Report Explored in Latest Research 2013 – 2019". Chicago Evening Post. Retrieved 30 May 2018.
- "Medical Discovery and Innovation, Preclinical Contract Research Services by Altogen Labs". GHP Magazine. April 2017. pp. 10–15. Retrieved 30 May 2018.
- "Altogen Labs Provides Biology CRO Contract Research Services to Accelerate Preclinical and Oncology Research Studies". Business Wire. 15 October 2013.
- "Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products". BioSpace. 29 October 2012. Retrieved 30 May 2018.
- United States Approved US20130330799 A1, "Crude oil degrading microorganisms and methods for their enhancement", issued 12 December 2013, assigned to Altogen Llc
This article "Altogen Labs CRO" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Altogen Labs CRO. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.